or an angiotensin receptor blocker (ARB), and 96% were on diuretics. We found that despite a high number of ED visits, the COACH group had no ED visits or hospitalizations for heart failure ...

For patients with heart failure, hospital participation in the IMPLEMENT-HF initiative improves adherence to quadruple ...

By blocking the effects of adrenaline, beta-blockers reduce the heart’s workload, which is especially beneficial for patients recovering from heart attacks or managing chronic heart failure.

They're prescribed to people with some irregular heart rhythms, heat attacks, heart failure, chest pain and other cardiovascular problems. Churchwell added beta blockers are one of the most ...

β-blockers may increase depression risk in heart attack survivors with normal heart function, questioning their necessity for this group. The REDUCE-AMI trial found long-term β-blocker use ...

The study ran from 2018 to 2023. "Beta blocker treatment led to a modest increase in depressive symptoms" for heart attack survivors who weren't in heart failure, the researchers reported.

The study ran from 2018 to 2023. "Beta blocker treatment led to a modest increase in depressive symptoms" for heart attack survivors who weren't in heart failure, the researchers reported.

Beta Blockers Unnecessary for Folks Without Heart Failure; May Be Linked to Depression By Ernie Mundell HealthDay Reporter TUESDAY, Nov. 12, 2024 (HealthDay News) -- Beta blockers are go-to meds ...

Beta blockers have long been included in the treatment regimen following acute myocardial infarction (AMI) for many patients, based primarily on dated research. 1 The results of a recent clinical ...

Glucagon is a pancreatic hormone that elevates blood glucose levels. Notably, testing a glucagon receptor blocker on a pre-clinical model of HFpEF resulted in significantly improved overall heart ...

BMJ. 2016;354:i4801. 5 Kim J, Kang D, Park H, et al. Long-term β-blocker therapy and clinical outcomes after acute myocardial infarction in patients without heart failure: nationwide cohort study.

ROCHESTER, N.Y. — The University of Rochester Medical Center announced a new federal grant, to the tune of $27 million, toward heart research. The focus will be on heart failure medication ...